Goldman Sachs Group Inc Maxcyte, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 505,388 shares of MXCT stock, worth $2.14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
505,388
Previous 347,853
45.29%
Holding current value
$2.14 Million
Previous $1.36 Million
44.17%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding MXCT
# of Institutions
124Shares Held
65.6MCall Options Held
1KPut Options Held
2K-
Cadian Capital Management, LP New York, NY8.19MShares$34.7 Million1.63% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$34.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.78MShares$24.5 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$21.4 Million7.62% of portfolio
-
Morgan Stanley New York, NY4.82MShares$20.4 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $431M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...